

1 **Table S1. Comprehensive analysis of QuantiFERON-TB Gold Plus indeterminate results.**

Case	Age	Gender	Setting	QFT CLIA (IU/mL)					QFT ELISA (IU/mL)					Lymphocytes (x10 <sup>9</sup> /L) <sup>a</sup>	Relevant clinical history
				Result	NIL	TB1- NIL	TB2- NIL	MIT- NIL	Result	NIL	TB1- NIL	TB2- NIL	MIT- NIL		
1	21	F	Outpatient	I	0.93	-0.11	-0.07	-0.01	I	0.42	-0.01	0.01	-0.01	0.03	Acute myeloid leukemia
2	55	M	Hospitalized	I	0.06	-0.01	-0.03	0.04	I	0.02	-0.01	-0.01	0.02	0.36	Severe COVID-19**
3	76	M	Hospitalized	I	0.04	-0.02	-0.02	0.40	I	0.03	-0.01	-0.01	0.14	0.20	Severe COVID-19**
4	44	M	Hospitalized	I	0.03	0.01	-0.01	0.37	I	0.06	-0.02	-0.02	0.20	1.43	Non COVID-19-related pneumonia
5	59	M	Hospitalized	I	0.02	-0.00	-0.00	0.11	I	0.01	0.01	0.01	0.06	0.53	Severe COVID-19**
6	80	M	Hospitalized	I	0.13	0.00	-0.00	0.35	I	0.08	0.01	0.00	0.22	1.14	Non COVID-19-related pneumonia
7	70	F	Hospitalized	I	0.04	0.01	-0.00	0.32	I	0.03	0.02	-0.01	0.14	0.61	Severe COVID-19**
8	49	F	Hospitalized	I	0.01	-0.00	0.00	0.06	I	0.02	0.00	-0.01	0.02	0.88	Severe COVID-19**
9	45	M	Hospitalized	I	0.03	0.01	0.01	0.05	I	0.02	-0.01	-0.01	0.03	1.12	Severe COVID-19**
10	53	M	Hospitalized	I	0.05	0.01	0.02	0.14	I	0.02	0.01	0.03	0.12	0.86	Severe COVID-19**
11	74	M	Hospitalized	I*	0.04	0.34	0.04	0.42	I*	0.03	0.20	0.01	0.26	1.01	Severe COVID-19**, and bladder cancer
12	81	M	Hospitalized	I	0.08	0.02	0.05	0.19	I	0.04	0.01	0.03	0.10	0.14	Severe COVID-19**, and history of kidney transplant
13	50	M	Hospitalized	I	0.15	-0.13	0.08	0.17	I	0.03	0.01	0.02	0.06	0.69	Severe COVID-19**
14	57	M	Hospitalized	I	0.00	0.08	0.10	0.41	I	0.02	0.02	0.02	0.19	0.64	Severe COVID-19**

2 \*Borderline results (equivocal range between 0.20-0.70 IU/mL).

3 \*\*Most severe COVID-19 patients were under treatment with immunosuppressive drugs (corticosteroids, tocilizumab, anakinra... etc.) at the  
4 time of the QuantiFERON-TB Gold Plus test.

5 <sup>a</sup>Lymphocyte count was determined at the time of the QuantiFERON-TB Gold Plus test.

- 6 Abbreviations: IU, international units; CLIA, chemiluminescence immunoassay; ELISA, enzyme-linked immunosorbent assay; MIT, mitogen; M,
- 7 male; F, female; I, indeterminate.